



# Colorectal Cancer Stem Cells in the Progression to Liver Metastasis

Carlos A. Gonzalez-Villarreal<sup>1†</sup>, Adriana G. Quiroz-Reyes<sup>2†</sup>, Jose F. Islas<sup>2</sup> and Elsa N. Garza-Treviño<sup>2\*</sup>

<sup>1</sup> Universidad de Monterrey, UDEM Vicerrectoria de Ciencias de la Salud, San Pedro Garza García, Mexico, <sup>2</sup> Universidad Autonoma de Nuevo Leon Facultad de Medicina, Departamento de Bioquímica y Medicina Molecular, San Nicolás de los Garza, Mexico

## OPEN ACCESS

### Edited by:

Antonella Zannetti,  
National Research Council (CNR), Italy

### Reviewed by:

Luigi Ippolito,  
University of Florence, Italy  
Francesco Merolla,  
University of Molise, Italy

### \*Correspondence:

Elsa N. Garza-Treviño  
egarza.nancy@gmail.com

<sup>†</sup>These authors have contributed  
equally to this work

### Specialty section:

This article was submitted to  
Molecular and Cellular Oncology,  
a section of the journal  
Frontiers in Oncology

**Received:** 14 March 2020

**Accepted:** 14 July 2020

**Published:** 20 August 2020

### Citation:

Gonzalez-Villarreal CA,  
Quiroz-Reyes AG, Islas JF and  
Garza-Treviño EN (2020) Colorectal  
Cancer Stem Cells in the Progression  
to Liver Metastasis.  
*Front. Oncol.* 10:1511.  
doi: 10.3389/fonc.2020.01511

Colorectal carcinoma (CRC) is a leading cause of cancer mortality. Tumorigenesis is a dynamic process wherein cancer stem cells (CSCs) and their microenvironment promote initiation, progression, and metastasis. Metastatic colonization is an inefficient process that is very complex and is poorly understood; however, in most cases, metastatic disease is not curable, and resistance mechanisms tend to develop against conventional treatments. An understanding of the underlying mechanisms and factors that contribute to the development of metastasis in CRC can aid in the search for specific therapeutic targets for improving standard treatments. In this review, we summarize current knowledge regarding tumor biology and the use of stroma cells as prognostic factors and inflammatory inducers associated with the use of tumor microenvironments as a promoter of cancer metastasis. Moreover, we look into the importance of CSC, pericytes, and circulating tumor cells as mechanisms that lead to liver metastasis, and we also focus on the cellular and molecular pathways that modulate and regulate epithelial–mesenchymal transition. Finally, we discuss a novel therapeutic target that can potentially eliminate CSCs as a CRC treatment.

**Keywords:** cancer stem cells, liver metastasis, epithelial–mesenchymal transition, pericytes, circulating tumor cells, metastasis, colorectal cancer

## INTRODUCTION

Colorectal carcinoma (CRC) is one of the most common tumors, with a global occurrence of over 2 million new cases each year (1). CRC represents the third most common cancer worldwide in terms of incidence and mortality for both men and women (2). Approximately 20–25% of patients with CRC already exhibit metastases at the time of diagnosis, and a striking 25% will develop metastatic spread during or after their follow-up (3). Briefly, CRC metastases begin with a series of mutations in the epithelial cells of the colon, continuing with the detachment of several cells from the primary tumor. This is followed by the invasion of surrounding tissue, diffusion through blood or lymphatic circulation, establishment, and finally, their proliferation to a distant location (1, 2).

Common sites of distant metastasis include the liver with a frequency of 60% and 25% to the peritoneum (3). Furthermore, the total number of metastases, tumor volume, and tumor microenvironment (TME) composition are strong predictors of prognosis (4). TME regulation is highly dependent on exosome production. Exosomes are extracellular vesicles (30–150 nm in diameter) that carry various contents such as growth factors, miRNAs, and enzymes. Sites of interactions between cancer cells and their microenvironment include blood vessels, extracellular matrix (ECM), signaling molecules such as transforming growth

factor-beta (TGF $\beta$ ), angiopoietin 1 and 2, platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF). They also include other tumor-recruited cells such as cancer-associated fibroblasts (CAFs), stromal myofibroblasts, endothelial cells, pericytes, diverse immune cells, mesenchymal stem cells, and cancer stem cells (CSC). All of these contribute to tumor growth and serve as a prerequisite for tumor cell invasion and metastasis (5). **Table 1** describes the participation of each cell type in the development or establishment of metastasis.

CSCs, also known as tumor-initiating cells, have recently been described as responsible for tumor growth, relapse, and treatment resistance. These cells represent a small subset of tumor cells (1–10%) that are involved in tumor development and self-renewal (6). They are crucial in maintaining stemness, tumor cell proliferation, and differentiation, and they are known to be regulated by pluripotency-related transcription factors such as OCT4, SOX2, KLF4, MYC, and NANOG. Moreover, these cells have been characterized and are known to present the following markers: CD44, CD24, CD133, CD166, LGR5, ALDH1, CD29, CD26, and CD51 (6, 21), all of which are not exclusive markers. When either CRC or CSC presents the CD51 marker and is co-localized with the TGF $\beta$  receptor, they can promote TGF $\beta$ /Smad signaling that upregulates epithelial–mesenchymal transition (EMT)-related genes, such as PAI1, MMP9, and Snail, which then promotes sphere formation, cell motility, and subsequent tumor formation (22, 23). Moreover, the standard form of CD44 (CD44s) is encoded by 10 constant exons. Alternative splicing generates CD44 variant isoforms (CD44v), of which specific isoforms are key in tumor development. Previously, studies on tissue CRC patients have shown that CSC-expressing CD44v6 permitted migration, enhanced autophagy flux, caused the phosphorylation of AKT and ERKs in the presence of a chemotherapy drug, and generated metastatic tumors; these were all associated with poor prognosis (24). Furthermore, the microenvironment surrounding CSCs plays an important role in supporting EMT induction, enhancing migration, homing, recolonization, and establishing metastasis (5).

## EPITHELIAL–MESENCHYMAL TRANSITION

EMT is a phenotype switch carried out by epithelial cells that enables them to assume a mesenchymal phenotype, thereby enhancing their migratory capacity, among other things (23). This process improves CSC proliferation and allows for the invasion of other tissues, thereby establishing metastasis. During EMT, metastasis begins with the loss of cell–cell junctions (based on cadherins, claudins, and occludins), secretion of enzymes (e.g., matrix metalloproteinases), and the loss of apical polarity due to the weak expression of cadherin–catenin anchorage to the cytoskeleton (25). It is worth noting that cadherins are among the cell adhesion molecules (CAMs) that include selectins, integrins, and proteoglycans. CAMs govern the assembly of cells into three-dimensional tissues, allowing epithelial cells to change to a mesenchymal phenotype, thus giving cancer cells acquired capabilities to extensively proliferate,

invade, migrate, and metastasize (26). The overall mechanism of EMT can be regulated in several ways such as through epigenetic regulation, growth factors, and transcription factors (27). Tight regulation of EMT permits the timely expression of important biomarkers such as N-cadherin, vimentin, smooth muscle actin alpha ( $\alpha$ -SMA), fibronectin, and other crucial regulatory factors such as the paired-related homeobox 1 (Prx1) (23). Prx1 functions in attenuating the complementary expression of Snail1, and the loss of Prx1 is required for CSC to colonize organs *in vivo*, which in turn reverts them to an epithelial state and removes the acquired CSC phenotype (28).

Transcription factors are proteins that enable the transcription of genes by binding to specific sites in the promoter region of a gene. Hence, in concert, they induce the activation of signals responsible for the regulation of proliferation, invasion, metastasis, differentiation, therapy resistance, and apoptosis of cells (29). As such, EMT progression requires the transcription factors Snail1 (Snail), Snail2 (Slug), Snail 3 (Smuc), basic helix–loop–helix factors (TWIST1/TWIST2), and zinc finger E-box binding homeobox (ZEB) (23, 25). EMT activation through transcription factors is illustrated in **Figure 1**.

The transcription factor Snail is promoted by upstream signaling of the hepatocyte growth factor, epidermal growth factor (EGF), fibroblast growth factor (FGF), and bone morphogenic protein, resulting in downstream binding to receptor tyrosine kinases (RTKs). Furthermore, both the RAS–MAPK and the PI3K–Akt pathways can also activate NF- $\kappa$ B, which consequently leads to Snail activation (30). An important trait of Snail is the SNAG domain in its N-terminus, which can recruit multiple chromatin enzymes such as HDAC, G9a, and Suv39H1 to the E-cadherin promoter. Chromatin modifications such as methylation at H3K27 can inhibit E-cadherin promoter activity (31). Moreover, Snail activates IL-8 expression by binding to its E3/E4 boxes, thus inducing cancer stem-like activities (32). Certain cytokines, such as tumor necrosis factor-alpha (TNF $\alpha$ ), can induce the degradation of I $\kappa$ B $\alpha$ , which is an inhibitor of NF- $\kappa$ B, and induce its nuclear translocation (33). This then induces the overexpression of Snail and other related genes (such as JUN) and correlates with both tumor and EMT progression (31).

As mentioned in other studies, TGF $\beta$  signaling plays an important role in EMT (30). TGF $\beta$  activates the Smad signaling pathway by binding to its receptors TGF $\beta$ RI/TGF $\beta$ RII, after which downstream effectors Smad2/Smad3 become phosphorylated. These then form a complex with Smad4, which induces the transcription of Snail1, vimentin, and fibronectin in CRC (31). Moreover, TGF $\beta$  signaling represses E-cadherin expression, which then initiates EMT (23). Furthermore, Snail1 activation also triggers FOXC1 expression, which is another EMT inducer, by upregulating the cysteine-rich angiogenic inducer 61 (Cyr61), which is a marker associated with metastasis by expression in CRC tissue (34).

The basic helix–loop–helix factor, TWIST, has an important role in metastasis, angiogenesis, chromosomal instability, and therapy resistance of tumors (30). Activation of its signaling pathway, along with Slug, leads to E-cadherin repression. Moreover, under hypoxic conditions, TWIST can regulate


**TABLE 1** | TME-associated cells.

Cell type	Identification markers	Normal activity	Prometastatic activity	References
CSC	Nanog Oct-4 SOX-2 Lgr-5 CD133 CD24 CD29 ALDH1 EpCAM CD44 CD166 CD26	Not present in healthy tissues	Tumor development, chemoattractant activity (SDF-1/CXCL12)	(6)
CAFs	CD44 a-SMA PDGFR- $\beta$ Desmin FAP FSP MFAP5 TN-C PDPN NG2	Extracellular matrix synthesis of collagen and elastin.	Secretion of growth factors EGF, IL-6, ILGF, HGF, improve angiogenesis, and remodel of ECM	(7–12)
MSCs	CD105 CD73 CD44 CD90	Components of stroma, immunomodulatory functions	Improve cell proliferation, angiogenesis, and metastasis by the secretion of CXCL12, IL-6, IL-8, and differentiation in CAFs	(11, 13, 14)
Pericytes	PDGFR $\beta$ CD13 NG2 CSPG4 a-SMA Desmin RGS5 CFTR/MRP SUR2 ALP Vimentin CD133 CD146.	Protection of endothelial cells in capillaries, blood flow regulation, and inflammatory cell trafficking	Secretion of growth factors HGF, FGFs, and CXCL12 that promote the growth, survival of malignant cells, and function as a chemoattractant	(5, 15–17)
Tregs	CD4 CD25 FoxP3 CD127	Maintenance of immune tolerance	Inactivation of CD8+ T-cells' cytotoxic activities, improvement of angiogenesis, and myeloid cell recruitment. Bad prognostic indicator	(11, 18–20)
Tumor-associated macrophages (TAM) -M1 -M2	CD14, CD16, CD64, CD68, CD71 CCR5	Proinflammatory cells specialized in pathogen destruction and enhancing activation of cytotoxic lymphocytes Anti-inflammatory cells that stimulate a CD4+ and regulatory T-cell response	Elimination of malignant cells. High production of NO TNF $\alpha$ , CXCL9, and CXCL10 Activate secretion of IL-6, TGF $\beta$ , EGF, bFGF, and IL-10, and VEGF to enhance tumor growth	(3, 11)

expression of the polycomb group RING finger protein BMI1 (BMI1) and promote the self-renewal of stem cells (31). The transcription factor TWIST-1 has also been reported to induce miR-10b, which promotes metastasis by targeting Homeobox D10 (HOXD10), which is associated with the inhibition of cell migration and may reduce E-cadherin expression, resulting in EMT (35); this mechanism is associated with hypermethylation of the miR-10 promoter in CRC tissues;

however, studies with greater samples and in different stages to know the role in CRC progression were necessary. In a recent study, miR-10b was found to target Kruppel Like Factor 4 (KLF4), resulting in a classically metastatic and aggressive phenotype (36), but the molecular mechanism in CRC is not known.

The zinc finger E-box binding homeobox 1 (ZEB1) protein is the main element in EMT (37). ZEB1 can regulate expression



of E-cadherin, vimentin, and various metalloproteases (25, 31). In CRC cells, ZEB1 can repress lethal giant larvae homolog 2 (LgI2) and promote metastasis (38). ZEB1 also contributes to the epigenetic silencing of E-cadherin and downregulates miR-34a expression. miR-34a helps remodel the cytoskeleton and improves the invasion and metastatic capabilities of CRC and colon CSC (39, 40). The invasiveness of a tumor can also be promoted by ZEB1 through the inhibition of plasminogen activator inhibitor-1 (PAI-1) and the activation of plasminogen activator (uPA); these are done by reducing its mRNA stability and through a mechanism involving histone acetyltransferase p300, respectively (31).

ZEB1 regulates other signaling pathways including TGFβ, Nanog, Notch, and canonical Wnt (β-catenin/TCF4) (41); this makes ZEB1 an ideal therapeutic target that can affect the population of CSC. Currently, there is no exclusive CSC marker nor an identified resistance mechanism that makes these cells less susceptible to conventional treatments. The miR200 family consisting of miR-200a, miR-200b, miR-141, and miR-429 (which all share a consensus seed sequence) have been gathering much attention, as they have been identified as key regulators of EMT,

and are involved in reverse transition (23, 41). Other miRNAs can regulate cancer-related genes such as oncogenes or genes implicated in cell growth, cell survival, angiogenesis, and tissue differentiation. It was found that a miR-181a gene target, WiF-1 (Wnt inhibitory factor 1), leads to a potent liver metastasis effect by suppressing epithelial markers such as E-cadherin and β-catenin and by overexpressing the mesenchymal marker vimentin found in CRC tumor tissues with liver metastasis (42). In contrast, miR-19a has been stated to promote proliferation and invasion by targeting T-cell intracellular antigen-1 (TIA1), which is an important tumor suppressor reported in colon cancer cells (*in vitro*) and in a xenografted mice model (*in vivo*). Conversely, it has also been reported to inhibit tumorigenesis; this occurs through angiogenesis inhibition as a result of KRAS targeting (43). miR-17-92a is an exosomal miR cluster widely regarded as a protumoral miR (44), whereas miR-885-5p is overexpressed during CRC liver metastasis by inhibiting the cytoplasmic polyadenylation element-binding protein 2 (CPEB2), resulting in TWIST upregulation, which then leads to EMT. Both are detected in serum and CRC tissue but this requires validation with a greater number of samples.

## CANCER STEM CELLS AND CIRCULATING TUMOR CELLS

As previously stated, epithelial tumor cells gain invasiveness and migratory abilities in the process of EMT; these are essential for successful metastatic spread and CSC generation (45). Diverse CSC clones can typically coexist within primary tumors, allowing for great intratumoral heterogeneity. After EMT, other CSC subpopulations may acquire properties such as quiescence, self-renewal, asymmetric division, drug resistance, and radiation resistance (46). Theoretically, under differing TME conditions, the CSC and non-CSC subpopulations undergo a dynamic conversion through EMT. Adversely, CSC can undergo the reverse mesenchymal–epithelial (MET) transition, which generates epithelial cells. These newly developed epithelial cells can be further extravasated into distant organs. It is known that disseminated cancer cells need to regain their epithelial phenotype to initiate the growth of a solid tumor at a secondary site (47).

Circulating tumor cells (CTC) are cells that have separated from the tumor mass and enter the bloodstream, and they originate either from primary sites or metastases that circulate freely in the peripheral blood. They have been detected in most epithelial cancers such as CRC (48). CTCs express similar markers as the cancer niche, and these markers are correlated with the occurrence of metastases and reduced survival in patients (49, 50). Furthermore, heterogeneous populations of CTC were detected as they demonstrated variants corresponding to different major regulatory pathways including KRAS, PIK3CA, and BRAF (51).

## METABOLISM CHARACTERISTICS OF CSC THAT ENHANCE INVASIVENESS

The altered metabolism of CSCs causes them to fail in efficiently producing ATP, in part due to the hypoxic environment. Therefore, fulfillment of much of the energy requirements comes from glycolysis, which is the fastest energy-producing pathway (52–54) due to the Warburg effect that is characterized by high pyruvate and low lactate production (55–57). Furthermore, the high volume of glycolysis intermediates is then used in the pentose phosphate pathway (PPP) to produce ribose, which is necessary for nucleotide synthesis and in anabolic reactions for lipid synthesis (56, 58).

Interestingly, the Warburg effect and the enhancement of the PPP in CSCs seem to be responsible for the enhanced production of antioxidant molecules and the overall reduction of reactive oxygen species (ROS) demonstrated *in vivo* and *in vitro* models (15, 55, 59). CD44 (CD44v) expression in CSCs suppresses PKM2 (mice model), thereby decreasing pyruvate dehydrogenase activity and promoting PPP; these are all consistent with the stabilization of the cysteine/glutamate antiporter and elevated GSH levels (58, 60–62). All these lead to higher survival rates of CSC even in hostile environments (15, 57, 58). In isolated CRC, miR-124, miR-137, and miR-340 have been reported as being able to switch the Warburg effect's glycolytic mechanism into

one involving oxidative phosphorylation in CRCs, which impairs cancer growth as a result (63). In the liver, miR-3662 suppresses the hypoxia-inducible factor (HIF)-1 $\alpha$ -mediated Warburg effect in hepatocellular carcinomas, which results in an antitumor effect (64). Other research groups have reported several other miRs with different important observations regarding the Warburg effect. First, miR-145 reduces the Warburg effect by KLF4 silencing in bladder cancer (65), and second, in breast cancer, miR-548a-3p targets sine oculis homeobox 1 (SIX1), which is a transcription factor that causes the Warburg effect, and miR-30a-5p targets the lactate dehydrogenase A (LDHA)-mediated Warburg effect, thereby suppressing tumor growth and metastasis (66, 67). The aforementioned studies were done using animal models, hence showing the true potential of miRs in the biological system. Yet, we believe a CRC-focused study is essential, given the complexity and the tissue-dependent role of miRs.

In the liver, aldolase B, which is one of the three aldolase isoforms, participates in the interconversion of both fructose-1-phosphate and fructose-1,6-bisphosphate to dihydroxyacetone and glycerol-3-phosphate, which acts as a rate-limiting step for fructose metabolism in the liver (68–73). Moreover, aldolase A and aldolase B have been linked to EMT in colon cancer, as they seem to interact with HIF-1 (74). Moreover, another study in mice showed that metastatic CRC cells in the liver upregulate aldolase B (ALDOB), which then promotes fructose metabolism to fuel glycolysis, gluconeogenesis, and PPP, which is a mechanism that is not seen in primary sites (75).

CSCs also heavily rely on glutamine for their metabolic needs; this is supplemented by conversion of other circulating branched-chain amino acids to glutamate and further aminated to glutamine. It is known that glutamine metabolism regulates the sensitivity of CSCs to metformin via the AMPK–mTOR pathway (76). Furthermore, glutamine can be hydrolyzed to glutamate which can be used to produce GSH (60–62).

Therefore, CSCs can switch between glycolysis and oxidative phosphorylation (OXPHOS), but they also can be influenced by the cancer stroma microenvironment. For example, CAF-secreted metabolites including lactate and ketone bodies can lead to OXPHOS (77). Moreover, CSCs relying on OXPHOS have better use of their limited nutrients (52), and even when OXPHOS operates at a lower rate, it represents a more efficient source of ATP, providing a selective survival advantage to the CSCs (78).

Beyond energy production, mitochondria are also involved in cellular redox rate, ROS generation, calcium buffering, synthesis of intermediate molecules as acetyl-CoA and pyrimidines, apoptosis regulation, and immune modulation (52, 79). In contrast to other cancer cells, CSCs have enhanced mitochondrial activity, more ROS and higher rates of oxygen consumption, and an apoptosis deficit. Moreover, they depend on fatty acid oxidation of ATP and on NADH generation (77). Mitochondrial DNA (mtDNA) is a factor that regulates this metabolic flexibility due to it possessing genes encoding the electron transport chain; abnormalities in the mtDNA are associated with cancer progression and metastasis (79). Enhanced mitochondrial biogenesis is also a key factor for CSC functionality, whereas an

increased mitochondrial mass can be used to identify cells with enhanced self-renewal capacity and chemoresistance (78).

A recent report on CRCs showed that cancer cells perform an alternative type of metabolism to reach the liver and establish secondary tumors. CRC cells induce the secretion of creatine kinase brain-type (CKB) into the microenvironment by downregulating miR-483 and miR-551a. CKB phosphorylates extracellular creatine to produce phosphocreatine, which is necessary to maintain cellular ATP levels. Moreover, the metastatic potential of cancer cells has been associated with the transcription co-activator peroxisome proliferator-activated receptor gamma co-activator 1 alpha (PGC-1 $\alpha$ ), which has been shown to couple oxygen consumption, OXPHOS, and mitochondrial biogenesis with the enhanced invasion characteristics of cancer cells (80).

Another metabolic stimulus derived from the TME is decreased extracellular pH levels, which are associated with CSC phenotypic features (e.g., slow-proliferating state, expression of stem cell markers, invasive capacities, and therapy resistance); this may also be involved in minimizing residual disease and long-term clinical dormancy/relapse (81). However, the transcriptional element sensitive to acidosis has not yet been reported. Decreased pH levels improve cell migration and invasion by enhancing the activity of matrix metalloproteinases and ECM remodeling (82). There have been clinical reports of pH effects on CRC liver metastasis, wherein acidic pH levels were associated with higher volumetric liver increase and a higher incidence of liver metastasis [62%] (83).

Hypoxia is a state characterized by low oxygen levels and, in cancer, is associated with changes in TME, leading to cancer progression. Under hypoxic conditions, CSCs express high levels of hypoxia-inducible factor 1 $\alpha$  (HIF-1 $\alpha$ ), which in turn promote migration, invasion, and EMT (84). Upregulation of HIF-1 $\alpha$  and HIF-2 $\alpha$  under hypoxic conditions activates the change from OXPHOS to glycolysis through the expression of GLUT1 and glycolytic enzymes such as LDHA and pyruvate dehydrogenase kinase (PDH). However, a master regulator of gene expression in cancer cells under acidic conditions is HIF-2 $\alpha$ , which acts through the activation of NAD<sup>+</sup>-dependent histone deacetylases (sirtuins) 1 and 6 (SIRT1/6), leading to the deacetylation of lysine residues in the HIF-2 $\alpha$  regulatory amino-terminal transactivation domain (N-TAD) (85). In a rat liver colon cancer metastasis model, cells were injected into the portal vein, after which it was established that decreased pH significantly enhanced liver metastasis (83). By altering the states of hypoxia and levels of pH, we can see the influence on the energy balance of cells which is a crucial step in regulating invasiveness of pH regulator molecules such as monocarboxylate transporters, V-type H<sup>+</sup> ATPases (V-ATPase), carbonic anhydrase (CA), Na<sup>+</sup>/H<sup>+</sup> Exchanger (NHE), and Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> anion exchanger 2 play critical roles in maintaining pH homeostasis. Regulation of pH through miR-34a and miR-34c has been reported to regulate lactate dehydrogenase. Moreover, miR-24 and miR-224 play crucial roles in cancer progression by regulating the expression of their target pH regulatory molecules CAIX, Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> anion exchanger 1, and SLC4A4 (a Na<sup>+</sup>-coupled HCO<sub>3</sub><sup>-</sup> transporter), respectively. Furthermore, miR-494 expression in intestinal epithelial cells

under acidic pH and lowered miR-224 expression in colorectal cancer are associated with methotrexate resistance (86).

Upregulation of miR-210 and miR-21 and downregulation of miR-126 expression are potential CRC biomarkers because of their participation in HIF-1 $\alpha$ /VEGF signaling during the initiation of colon cancer. In a hypoxic microenvironment, achaete scute-like 2 (Ascl2) is overexpressed, leading to EMT by miR-200b repression while allowing regulatory feedback for CRC EMT-MET plasticity. Conversely, miR-199a downregulation has been associated with metastasis in CRC by enhancing HIF-1 $\alpha$ /VEGF expression. In CRC, p53 downregulates miR-107, which, in turn, enhances HIF-1 $\beta$  expression. miR-107 overexpression reduces tumor growth, VEGF expression, and angiogenesis. Moreover, in CRC, miR-145 expression is reduced, which can regulate p70S6K1 expression, which, in turn, targets HIF-1 $\alpha$  and VEGF. miR-145 expression is negatively correlated with p70S6K1, which acts as a tumor suppressor in CRC (87).

In TME, hypoxia attracts tumor-associated macrophages (TAMs), which through IL-10 and IL-12 contribute to migration, invasion, and metastasis; moreover, adipocytes provide fatty acids as an energy source (88). Endothelial cells increase the expression of miR-210 via HIF-1 $\alpha$ , which downregulates ephrin A3, resulting in decreased migration and decreased capillary-like endothelial cells (89). At the same time, HIF-1 $\alpha$  contributes to autophagy and aerobic glycolysis, stimulating CAF, which contributes to tumor progression (84). Furthermore, hypoxia has been shown to increase the secretion of tumor-derived procollagen-lysine and 1-oxoglutarate 5-dioxygenase (PLOD1). PLOD1, which is an HIF target that hydroxylates lysine residues on collagen, promoting the formation of mature collagen crosslinks, which has been reported to facilitate metastasis (90). Moreover, it is worth noting that PLOD1 expression is upregulated in gastrointestinal cancer compared with normal tissues, predominantly in gastric cancer associated with the overexpression of p53 (91).

Under these conditions, CSC is more resistant to chemotherapy and radiotherapy because of the induction of HIF signaling and upregulation of stem pathways such as CD44 and Notch. Furthermore, CSC is more resistant because of lower ROS production. Moreover, CSC in a hypoxic microenvironment demonstrates immunosuppressive and immune evasion properties: for example, VEGF suppresses dendritic cell function and promotes the expression of PD1 ligand (PD-L1), which generates resistance to cell immunity. In clinical settings, the use of anti-PDL1 drugs is currently becoming an adopted strategy. Also, a downregulation of MHC complexes occurs that leads to immunosuppressive effects (92). Although HIF-1 $\alpha$  expression is not associated with the primary lesion, it may be used as a prognostic marker in metastasis.

## MIGRATING CSC AND METASTASIS

The spread of colorectal CSC from the primary tumor to a secondary tumor requires phenotype changes such as the development of CTC. They require the formation of clusters

together with stromal cells (e.g., fibroblasts, endothelial, tumor-infiltrated myeloid cells, or pericytes) to increase the viability of tumor progression, as shown in **Figure 2**. Pericytes promote the formation of CTC groups termed as circulating tumor microemboli, which are formed by 2–50 CTC with improved metastatic potential and tumor progression (15, 93).

As previously mentioned, certain CTC have all the hallmarks of CSC. They could develop metastasis, including the shedding and invasion of primary cancer cells into the circulatory system. They also have the abilities of migration, penetration of the vascular endothelial cell layer, tissue invasion, cell proliferation, and angiogenesis (93). Moreover, during tumor progression, some of the epithelial cells convert to CSC through EMT, thereby promoting angiogenesis. *In vitro*, these endothelial cells can transdifferentiate and acquire mesenchymal or myofibroblastic markers such as  $\alpha$ -SMA and type I collagen with the stimulation of growth factors such as TGF $\beta$ , which leads to endothelial cytoskeleton remodeling and increased vessel permeability (94). Although there are other mechanisms of tumor dissemination and metastasis progression, we will focus on the most reported.

During cancer, EMT is regulated by extracellular stimuli derived from TME such as growth factors, cytokines, and physical stresses including hypoxia (45). Growth factors such as TGF $\beta$  can inhibit E-cadherin expression, which stimulates the relocation of the membrane in CRC during the invasion step (23). In detail, TGF $\beta$  production is stimulated by hypoxic stress from myeloid cells, mesenchymal cells, and CSC. Development of hypoxia activates genes encoding glucose transport, glycolytic enzymes, VEGF, PDGF, bFGF, erythropoietin, angiopoietin, and placental growth factor (95). Combined, these genes help promote angiogenesis and metastasis (90).

Recently, stem cell markers have been used to identify three CSC subpopulations within liver metastasis from CRC samples isolated from patients. One population within the tumor niche had the markers SOX2<sup>+</sup>/NANOG<sup>+</sup>/KLF4<sup>+</sup>/c-MYC<sup>+</sup>/OCT4<sup>-</sup>, and two populations in the peritumoral stroma had the markers SOX2<sup>+</sup>/NANOG<sup>+</sup>/KLF4<sup>+</sup>/c-MYC<sup>+</sup>/OCT4<sup>-</sup> and SOX2<sup>+</sup>/NANOG<sup>+</sup>/KLF4<sup>+</sup>/c-MYC<sup>+</sup>/OCT4<sup>+</sup>. The presence of OCT4 in the stroma was theorized to represent the most primitive subpopulation of CSC. This report showed that a highly specialized microenvironment plays an important role in maintaining the stem cell pool in liver metastasis (96). Interestingly, this specialized microenvironment can express components of the renin-angiotensin system (PRR, ACE, ATIIR1, and ATIIR2) in a wide variety of cancers including CRC (97). Stromal cell-derived factor 1 (SDF-1) is another factor that upregulates E-cadherin expression. The process of E-cadherin redistribution on the cell surface indicates that EMT has a regulation that seems to be crucial in tumor spread; however, more analyses of epithelial status at different stages of the metastasis process is needed. Moreover, SDF-1 is expressed in stromal cells such as fibroblasts and endothelial cells *in vitro*, and its interaction with the CXCR4 receptor on the CSC improves CRC liver metastasis because of its chemoattractant role (98).

Pericytes and endothelial cells promote intravasation, which is the process wherein cancer cells move into the blood and lymphatic flow (15); however, tumor progress for angiogenesis

due to the increased expression of metalloproteases and growth factors depends on the high expression of VEGF-A and Wnt7B, which are both expressed by macrophages that co-express Tie2. These macrophages mediate the loosening of vascular junction and enhance vascular permeability and MMP-9 expression by tumor-associated neutrophils. MMPs (MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, and MT1-MMP) degrade the ECM, which then facilitates the extravasation of tumor cells and CSC (99). Endothelial cells, pericytes, and TAMs contribute to tumor intravasation by performing pro-angiogenic effects; conversely, VEGF, colony-stimulating factor-1 (CSF-1), and Ang2 induce neo-vessel formation via the expression of interleukin 8 (IL-8) (5, 100) in murine cancer models.


Not all CTC or CSC that undergo extravasation can generate metastases. Some CTC are not completely differentiated and have both epithelial cell markers such as epithelial CAM and mesenchymal cyokeratin markers such as cytokeratin (CK)-8, CK18, and CK19 (48). Subclones with an intermediate phenotype are known to have the greatest plasticity for microenvironment adaptation. These populations generate a more aggressive cell type with resistance to therapy and metastatic growth in breast cancer (101).

Aside from the difference between CTCs and primary tumor cells, heterogeneity also exists in different CTC subpopulations. Malara et al. showed different biological behaviors in two expanded CTC (eCTCs) subpopulations derived from patients with colon cancer. First, an eCTC subpopulation expressed CXCR4<sup>+</sup>CK20<sup>+</sup>; these were not tumorigenic cells. Next, a second eCTC subpopulation that additionally expressed CD45<sup>-</sup>CD133<sup>+</sup> were tumorigenic. Patients with different CTC prevalence had different clinical outcomes (102). Thus, on the basis of this heterogeneous CTC composition, many researchers now believe that traditional clinical treatment strategies might not be useful for patients with metastasis, as these strategies are often based on the pathological and molecular characteristics of the primary tumor. This shows that CSC migration and metastasis are achieved by a combination of characteristics from cells; also, these microenvironments have been studied by different groups; nonetheless, CSC are capable of changing these properties to improve their survival and metastasis.

## PRE-METASTATIC NICHE

CTC invasion requires preparation of the microenvironment to allow for the development of metastasis (93). To establish the pre-metastatic niche, a series of contributors are necessary: (1) tumor-derived secreted factors, (2) extracellular vesicles, (3) immune cells, and (4) cell and molecular changes in distant organs that promote mobilization of bone marrow-derived cells and contribute to niche formation and tumor cell homing (103, 104).

In recent years, small non-coding RNAs such as microRNA (miR) have gained traction for their roles as regulatory factors in angiogenesis or in tumor metastasis during CRC (18, 104), as shown in **Table 2**. Other components of microenvironments involved in CRC progression to liver metastasis include immune cells such as CD11b<sup>+</sup> myeloid cells that express



integrins and various chemokines (CXCR2-CXCL1, CXCL12-CXCR4, and CCL12-CCR1) studied in a murine model of liver metastasis (126). Moreover, tumors and endothelial cells express sphingosine-1-phosphate receptor 1 (S1PR1) in a CRC murine model, which is a key element involved in the persistent activation of signal transducer and activator of transcription-3 (STAT3). STAT3 regulates inflammatory mediators (e.g., IL-6, IL-10, and TNF $\alpha$ , and GM-CSF) (127). Similarly involved are TAMs that release factors that contribute to tumor growth, immunotolerance, angiogenesis, and therapy resistance. M2 macrophages have protumor activity and are recruited in the metastatic and pre-metastatic niche by the cytokines CCL2, CCL5, VEGF, and CSF-1. *In vitro* studies have shown that in primary tumor, CAFs secrete fibronectin and lactate, which, when accumulated, have an inhibitory effect on natural killer (NK) cell activity while concomitantly promoting the expansion of M2 macrophages (Figure 2) (128, 129).

Liver metastasis in CRC patients, which is not the only one presented, is most common because of the anatomical situation related to portal circulation (2). Once CSCs lose

intercellular junctions in the primary tumor, they can diffuse through blood or lymphatic circulation and migrate into the portal system to the liver. They can traverse the endothelial barrier of the portal vessels, attach to hepatic sinusoids, and interact with sinusoid cells, Kupffer cells (KCs), hepatic stellate cells (HSCs), liver sinusoidal endothelial cells (LSECs), dendritic cells, liver-associated lymphocytes, and portal fibroblasts. ECM collagen and the cellular components of the liver adapt to the hypoxic environment, begin angiogenesis, and finally expand and metastasize. Metastatic lesions regularly respect the hepatic capsule and intersegmental layers, thus respecting nearby structures (130, 131); this process is illustrated in Figure 3.

Based on a large number of studies, liver metastasis progress is divided into four phases: (1) CSC liver infiltration, (2) interlobular micrometastasis, (3) angiogenesis, and (4) established hepatic metastasis (131). The first phase occurs within the sinusoids, whereas the following steps are further metastatic steps that affect the inner hepatic parenchyma. Moreover, resident cells generate multiple tumorigenic effects, promoting either elimination, CTC, or liver colonization. Here, a set of

**TABLE 2** | miRNAs in premetastatic and metastatic niche.

	miRNAs	Expression	Function in cancer	Target	References
Pre-niche	miR-25-3p	Endothelial cells	Angiogenesis	KLF2 and KLF4	(105)
	miR-21*	Cancer cells	Proliferation	PDCD4	(106)
	miR-17*	Serum	Invasion Cell infiltration	PRL-3/STAT3	
	miR-19	Cancer cells	An enzyme of ECM and TME	TG2	(107)
	miR-885-5p	Cancer cells	Migration, invasion	Cpeb2	(108)
	miR-20a-5p	Stromal cells	Invasion and metastasis	Smad4	(109)
	miRNA-155*	Cancer cells	Migration and invasion Lymph node metastasis	PTPRJ TP53INP1	(110)
	miR-181a	Cancer cells	Promotes EMT and liver metastasis	WIF-1	(111)
	miR-429	Cancer cells	Inhibits apoptosis Promotes EMT	HOXA5 SOX2	(112) (113)
	Metastatic- niche	miR-527/665	CRC cells	Metastasis	KSRP SMAD4 TGF $\beta$ R2
miR-34a		Serum	Establishes metastasis	EGR1	(115)
miR-99b-5p*		Liver metastasis	Inhibits rapamycin expression, tumor-suppressing miRNA, good prognostic	mTOR	(116)
miR-377*		Liver metastasis	Lymph node metastasis, poor prognostic	p53, PTEN, and TIMP1	(116, 117)
miR-200c, miR-196b-5p*		Liver metastasis, serum	Mediate epithelial-mesenchymal transition	TGF-TGF $\beta$ signal pathway	(116, 118, 119)
miR-146a, miR-146a-5p		CRC cells	Migration and invasion	c-met, CPM (carboxypeptidase M)	(120, 121)
miR-125, miR-127, miR-145, miR-194, and miR-199a-30*		stroma and tumor	Tumor suppressors, inhibit cell proliferation, motility, invasion, angiogenesis	c-Myc, KRAS, and MAPK4, BMP1, CDKN1B, mTOR, c-MET, ERK2,	(122, 123)
Let-7a, miR-126, miR-141, and miR-21		Serum	Metastasis	KRAS, NIRF, IGFBP2, PITPNC1 MERTK ZEB1 and ZEB2 PTEN, Pdcd4, TPM1	(122, 124)
miR-19a*, miR-19b, miR-23a, miR-92a, miR-320a and miR-4437		Serum	Inflammation, fibrosis, angiogenesis, liver metastasis, bad prognostic	TIA1 PTEN	(113, 123, 125)

\*Potential biomarker.

molecular pathways are involved including nitric oxide and ROS, as well as the expression of adhesion molecules such as selectins and integrins by the same cells. Also involved are phagocytosis, cytokines such as TNF $\alpha$  and TGF $\beta$ , interferon gamma (IFN $\gamma$ ), interleukins (IL-1, IL6, IL8, IL-10, IL12, and IL18), growth factor monocyte chemoattract protein-1 (MCP-1), and macrophage inflammatory protein (MIP-1) released by KCs and HSCs (132).


As mentioned before, macrophages are recruited to the liver transfer exosomes and to the KC, secreting TGF $\beta$ , which then promotes the production of fibronectin by HSC. When fibronectin accumulates, TAMs are recruited and form the pre-niche (**Figure 3**) (131). This was confirmed in a murine model of metastatic pancreatic ductal adenocarcinoma (PDAC). Expression of granulins by macrophages stimulates HSC for differentiation into myofibroblasts, which in turn releases periostin, creating a fibrotic environment in the liver that sustains tumor growth (133). Similarly, human hepatic sinusoidal endothelial cells *in vitro* express macrophage

migration inhibitory factor (MIF-1), which induces EMT, migration, proliferation, and apoptotic resistance in CRC cells (134). Finally, angiopoietin-like 6 protein from the LSEC induces liver colonization of CRC cells and correlates with CRC progression in *in vitro* models (135).

The liver suffers different changes from correct establishment of metastasis, generated mainly due to CSC and its released factors. Moreover, other factors such as genetic mutations or epigenetic changes that improve CSC colonization in different tissue should be studied.

## LIVER METASTASIS AND COLORECTAL CANCER

Once the microenvironment in the liver has been achieved, a series of changes occur in the cellular architecture that can lead to an inflammatory response (e.g., IL6-STAT3), which leads to




metastasis in aggravated cases (136–138). The elevated expression of CD66e, which is also known as the carcinoembryonic antigen (CEA) or CEACAM5, is a common change because it is a widely expressed receptor in human carcinomas. Therefore, CEACAM5 is currently being evaluated as a determinant of the CRC state as its elevation is associated with metastasis (139, 140).

CEACAM5 affects the liver as follows: first, it protects circulating CRC cells from death through the inhibition of anoikis (an apoptosis mechanism in detached cells that occurs through a TRAIL-DR5 translocation). CEACAM5 binds the human RNA binding protein M4 in KC, and consequently blocks downstream translocation of DR5. Second, the bound form of CEACAM enhances the KC microenvironment by activating fibroblasts, which in turn facilitate CRC growth (139, 141). ECM expression of the  $\alpha 5\beta 1$  integrin/fibronectin interaction then leads to cell survival (142–144). Finally, CEACAM5 upregulates adhesion molecules such as E-cadherin and N-cadherin, thereby promoting aggregation (cell survival) and metastasis (139, 140, 144–146). Closely related is CD66c (or CEAMCAM6), which has also been implicated in reducing life expectancy, as it has been identified to be involved in similar signaling strategies (141, 147). A unique feature of CEACAM6 is its promotion of HER2 and  $TGF\beta$  interactions. Overexpression of CEACAM6 increases SRC activity, leading to the enhancement of IGF-1 secretion resulting in MMP-2 and MMP-7 activation and ECM rearrangement (147).

This knowledge has been demonstrated *in vitro* and clinical data; however, detailed mechanisms remain to be elucidated.

Increased accumulation of mutations in genes encoding downstream signaling pathways are well-studied drivers of CRC metastasis. Studies have shown that mutations in the MAPK/ERK pathway (KRAS), p53 pathway (TP53), Wnt/ $\beta$  catenin pathway (APC), and the PI3K/Atk pathway (PIK3CA) in clinical CRC samples from patients are the most influential drivers of liver metastasis. These have emerged as the most important biomarkers that determine the biological state of the tumor and provide clinical significance to patient outcomes (148–150).

The RAS family of proteins belongs to the guanosine-5'-triphosphatase family, among which KRAS is a well-studied member. Primarily functioning as a signal transducer, KRAS can work both as a positive and negative stimulator of the MAPK/ERK signaling pathway and is activated by ligands binding to RTKs (151). When activated, KRAS becomes adherent to the membrane by the prenylation of the CAAX domain with farnesyl transferase, subsequently inducing SOS1/2 phosphorylation. Primarily, activated RAS can signal either the PI3K or MAPK pathways. In CRC, KRAS activation has been associated with rapid and aggressive metastasis to the liver (150, 152). Further mutations such as KRASQ61, overamplify the effects of EGF even at low concentrations, whereas KRASG12 requires a translocation to become active, in all cases causing



a positive feedback over the RAS-RAF-MEK-ERK axis (153) resulting in increased cell proliferation.

Moreover, IGF-1R (Insulin-like Growth Factor 1 Receptor) seems to increase during the anti-EGF state by immunotherapy. Both IGF-1R and STAT3 stimulate CRC development due to microenvironmental effects (6). CRC cells tested with monoclonal antibodies showed not only IGF-1R mRNA overexpression but also the overexpression of PI3K (153, 154). Interestingly, the PI3K/Akt pathway activates during EGF resistance, and its inhibition reverses resistance. A further IGF-1R knockdown blocks Akt activation, which is a known therapeutic target. Therefore, it is postulated that IGF-1R, as well as PIK3CA (the PI3K subunit), can induce secondary resistance to anti-EGFR therapy in CRC (153).

TP53 acquired mutations have been shown to affect a plethora of cancers including colon, stomach, breast, lung, brain, and esophageal cancers, and estimations indicate that over 50% of all cancer cases contain TP53 mutations (154–159). In CRC, missense mutations in the DNA binding domain lead to its oncogenicity. Several p53 amino acid hotspots such as R175, G245, R248, R249, R273, and R282 are known to induce “gain of function” properties. Moreover, these malignant mutations are correlated to a poor survival rate in patients; as such, these function as crucial survival biomarkers (160). These mutations are known to translocate

with p63 (DNp63a) and p73, which accelerate TGF $\beta$  (increase RhoA activity) or the proto-oncogene BRAF (through EGF) metastasis (157, 161). A mechanism involving  $\Delta$ Np63 $\alpha$  (1 of 5 possible Tap64 isoforms related with oncogenic properties) activated by miR-527/665 repression suppresses the KSRP regulatory factor thus, miR-198 (a regulatory miR) switches off upregulating SMAD4 and TGF $\beta$ R2 (114) *in-vitro* and *in-vivo*. In conclusion, in addition to the well-known role of TPs oncogenes, the microRNA network is largely implicated in cell development and upkeep, and is currently the focus of many research groups.

Additionally, R248Q and R273C have been reported to bind and induce histone acetylation and increase HER2 protein levels, which is typically observed in 5–14% of RAS- and IGF-related CRC (147, 162, 163). Another important aspect of survival is the upregulation of NF- $\kappa$ B and TNF $\alpha$  by blocking the effects of the tumor suppressor protein DAB2IP, as p53 mutants provide activation by increasing the production of cytokines IL-6, IL-11, and IL-23 (pro-angiogenic), as well as the production of cancer cells due to cytotoxic effects happening in the environment (Figure 4). Directed rearrangement to the microenvironment regulated by p53 mutants is exhibited as a high expression of CXCL5, CXCL8, and CXCL12, which endorses cells to migrate, grow, and invade and reshape antitumor mechanisms to its advantage as part of chronic tumor adaptation and growth (157).

APC mutants have been found in over 80% of CRC patients; additionally, hypermethylation has been described in nearly 20% of patients (164). Recently, a new player has emerged for its direct role in mediating functions of a mutated APC, namely, lncRNA-APC1. lncRNA (long non-coding RNA) APC1 is a downstream effector of APC and is independent of  $\beta$ -catenin (normally, it serves as a regulatory negative feedback product). It exerts strong antiangiogenic effect *in vivo* and in xenograft murine models by remarkably reducing exosome production through the Rab proteins (Ras mediates signaling). Rab5b levels seem to be upregulated during lncRNA-APC1 silencing in CRC, which, when further tested, has its silencing correlated to cell proliferation. Furthermore, subsequent testing demonstrated p38/MAPK, JNK, ATK, and Rho dependency on exosome production (165).

PIK3CA gene encodes for the p110 $\alpha$  subunit of type I PI3Ka, and mutations in this gene are prevalent in ~30% of CRCs. Its primary function is to produce PIP3 as a way of inducing PDK1 and ATK signaling. PI3K expression combined with the loss of APC activity concludes in metastasis. It should be noted that both PI3K and APC mutants are strong biomarkers because their levels can help indicate a response to chemotherapy in preoperative patients (148).

As mentioned above, many aspects of liver metastasis have been revealed; however, better understanding of the biomarkers that have been reported as therapeutic targets is still required. There also exists the question: to what extent can the damage caused to the liver be reversible through therapeutic strategies? What we know is that out of the patients who undergo liver resectioning as a treatment, 75% have recurrence within the first 2 years after surgery that can be both intrahepatic and extrahepatic (146, 166). Therefore, new approaches that are specific against relevant cell populations, or are triggered by remaining cell types, are required to promote metastasis. Lastly, the underlying role of exosome-mediated extracellular communication has been progressively elucidated; its cargo, namely, proteins, transcription factors, growth factors, and several miRs (oncomirs) have been identified as important biomarkers, chemotherapy resistance, of prognostic value or very plausible therapeutic targets.

## CSC POTENTIAL THERAPEUTIC TARGETS

Based on the various biological characteristics of CSCs, it is clear that they represent important targets against tumor progression and metastasis (6). Targeting CSCs via their unique signaling pathways (Sonic hedgehog (Shh)/Patched (Ptch)/Smoothed (Smo), Notch/Delta-like ligand (DLL), CXCR chemokine receptor 1-2/CXCL8/FAK, Wnt,  $\beta$ -catenin, STAT3, and Nanog), metabolic reprogramming, targeting ABC transporters, and the use of non-coding RNA, represent promising strategies (167, 168). Napabucasin is a first-in-class cancer stemness inhibitor that targets STAT3. Furthermore, clinical evaluation of napabucasin was recently completed in a phase III clinical trial in CRC patients. Although no significant difference in overall survival was seen when comparing between the napabucasin and placebo

treatment groups, in a subgroup of patients with pSTAT3-positive tumors, napabucasin treatment led to improved survival (169). However, because of the inherent heterogeneity of CSCs, targeting a single molecule or pathway may not be an effective strategy since CRC (and most cancers) rely on alternative pathways to avoid cancer checkpoints; therefore, encompassing most pathways may dictate better therapy; some of these are discussed later.

Immunotherapy represents an important emerging field in tumor therapy (170). A chimeric antigen receptor-modified T-cell (CAR-T) cocktail immunotherapy targeting CD133 and EGFR showed a longer partial response than single CAR-T target therapy in a patient with advanced CRC (171). Immune checkpoint inhibition is another immunotherapy strategy that has been recently applied to CRC. Programmed cell death protein 1 (PD-1) is expressed in T-cells, and PD-L1 is constitutively expressed in cancer cells. PD-L1/PD-1 interaction dysregulates T-cell activity, inducing exhaustion, apoptosis, neutralization, and promoting the production of IL-10, which in turn reduces cytotoxic T-cell (CD8+) activity, promoting cancer development and progression by enhancing tumor cell proliferation and survival (172). The PD-1/PD-L1 blockade has shown positive results in CRC patients with microsatellite instability-high or MMR-deficient (MSI-H) cancers, which is a type of CRC characterized by high somatic mutations (173). In 2017, both PD-1 inhibitors nivolumab and pembrolizumab were approved for the treatment of MSI-H CRC in the United States for treatment-refractory metastatic CRC (170). Pembrolizumab and nivolumab, under the commercial names of Keytruda and OPDIVO, respectively, have been approved by the FDA since 2014. Nevertheless, for better results, CRC immunotherapy requires a combination of PD-1/L1 and/or CTLA4 inhibition agents such as Nivolumab and Ipilimumab. Several TME factors may contribute to this therapy such as low T-cell infiltration, low number of type 1 T-helper cell activity, and low immune cytotoxicity (170).

Another approach of this type of CRC therapy is the use of vaccines with only peptides, peptide-expressing viruses, peptide-loaded antigen-presenting cells, or the application of peptide-specific T-cells that bind to human leukocyte antigen so that they can be recognized by T-cells for a specific antitumoral immune response. One of the first tumor-associated antigens ever identified was the CEA, which is also overexpressed in CRC as mentioned before (174). There are ongoing clinical trials of this type of immunotherapy in metastatic colorectal cancer (NCT03555149, NCT00154713, NCT02380443, and NCT04110093) in Phase II.

Although this is a very promising strategy because of it can regulate expression, the TME still plays a key role in progression; therefore, current treatments should focus on combining different strategies by attacking the primary tumor and metastasizing it against different cell targets. One of the most promising is the use of miR as therapeutic targets since these are specific and do not develop resistance. These are directed not only against CSCs (40) but also against pericytes and endothelial or inflammatory cells that promote tumor angiogenesis and metastasis.

As mentioned above, many aspects of liver CSC biology have been revealed through great efforts and contributions by various research groups. However, various physiological and mechanistic questions regarding liver CSCs remain to be elucidated. The current understanding of biomarkers has given us several tools to better diagnose and understand the future of prognosis in patients with CRC and liver metastasis. Known protein interactions, mutations, and other gene and protein identification techniques are at the forefront of current clinical usage (169).

## CONCLUSION

Many aspects of liver CSC biology have been revealed through great efforts, which have contributed in the elucidation of the important role of exosomes and miRs. Both of these are key components with proven roles in helping establish the pre-metastatic niche, participating in TME development, assisting in angiogenesis, and, most importantly, dictating micrometastasis regulation. Furthermore, both exosomes and miRs tend to favor pathways that induce chemoresistance in cells, as well those that aid cell invasion through EMT. However, various physiological and mechanistic questions of the roles CSCs play in liver

metastasis remain to be elucidated, such as those regarding certain regulatory factors, which undoubtedly will be the next therapeutic targets in the study of metastasis.

Our current understanding of biomarkers has given us several tools to better diagnose and understand the future of prognosis in patients with CRC and liver metastasis. Known protein interactions, mutations, and other gene and protein identification techniques are at the forefront of modern-day clinical use. Currently at its early stages, research on miRs seems to have great potential as many miRs tend to be exported by exosomes. These miRs can be directly detected in serum, blood, urine, and other major fluids; hence, studies that combine multiple techniques and novel therapeutic approaches will improve the prognosis of liver metastasis in CRC patients.

## AUTHOR CONTRIBUTIONS

AQ-R and EG-T performed literature analysis and wrote, discussed the revised manuscript, and designed the images. JI wrote, analyzed, and corrected the manuscript. CG-V performed literature analysis and wrote part of the text. All authors read and approved the final manuscript.

## REFERENCES

- Mármol I, Sánchez-de-Diego C, Dieste A, Cerrada E, Rodriguez MJ. Colorectal carcinoma : a general overview and future perspectives in colorectal cancer. *Int J Cancer*. (2017) 18:197. doi: 10.3390/ijms18010197
- Zarour LR, Anand S, Billingsley KG, Bisson WH, Cercek A, Clarke MF, et al. Colorectal cancer liver metastasis: evolving paradigms and future directions. *CMGH*. (2017) 3:163–73. doi: 10.1016/j.jcmgh.2017.01.006
- Pretzsch E, Bösch F, Neumann J, Ganschow P, Bazhin A, Guba M, et al. Mechanisms of metastasis in colorectal cancer and metastatic organotropism: hematogenous versus peritoneal spread. *J Oncol*. (2019) 2019:1–13. doi: 10.1155/2019/7407190
- Wu T, Dai Y. Tumor microenvironment and therapeutic response. *Cancer Lett*. (2017) 387:61–8. doi: 10.1016/j.canlet.2016.01.043
- Hui L, Chen Y. Tumor microenvironment: sanctuary of the devil. *Cancer Lett*. (2015) 368:7–13. doi: 10.1016/j.canlet.2015.07.039
- Fanali C, Lucchetti D, Farina M, Corbi M, Cufino V, Cittadini A, et al. Cancer stem cells in colorectal cancer from pathogenesis to therapy : controversies and perspectives. *World J Stem Cells*. (2014) 20:923–42. doi: 10.3748/wjg.v20.i4.923
- Herrera M, Herrera A, Domínguez G, Silva J, García V, García JM, et al. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. *Cancer Sci*. (2013) 104:437–44. doi: 10.1111/cas.12096
- Zhang R, Qi F, Shao S, Li G, Feng Y. Human colorectal cancer - derived carcinoma associated fibroblasts promote CD44 - mediated adhesion of colorectal cancer cells to endothelial cells by secretion of HGF. *Cancer Cell Int*. (2019) 19:192. doi: 10.1186/s12935-019-0914-y
- Monteran L, Erez N. The dark side of fibroblasts : cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. *Front Immunol*. (2019) 10:1835. doi: 10.3389/fimmu.2019.01835
- Lynch MD, Watt FM, Lynch MD, Watt FM. Fibroblast heterogeneity : implications for human disease find the latest version : fibroblast heterogeneity : implications for human disease. *JCI*. (2018) 128:26–35. doi: 10.1172/JCI93555
- Irani S. Emerging insights into the biology of metastasis : a review article. *Iran J Basic Med Sci*. (2019) 22:833–47. doi: 10.22038/ijbms.2019.32786.7839
- Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E. In search of definitions: cancer-associated fibroblasts and their markers. *Int J Cancer*. (2020) 146:895–905. doi: 10.1002/ijc.32193
- Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Kodama M, Higashi Y, et al. Mesenchymal stem cells enhance growth and metastasis of colon cancer. *Int J Cancer*. (2010) 127:2323–33. doi: 10.1002/ijc.25440
- Li N, Hua J. Interactions between mesenchymal stem cells and the immune system. *Cell Mol Life Sci*. (2017) 74:2345–60. doi: 10.1007/s00018-017-2473-5
- Garza Treviño EN, González PD, Valencia Salgado CI, Martínez Garza A. Effects of pericytes and colon cancer stem cells in the tumor microenvironment. *Cancer Cell Int*. (2019) 19:173. doi: 10.1186/s12935-019-0888-9
- Attwell D, Mishra A, Hall CN, O'Farrell FM, Dalkara T. What is a pericyte? *J Cereb Blood Flow Metab*. (2016) 36:451–5. doi: 10.1177/0271678X15610340
- Wong S, Rowley JE, Redpath AN, Tilman JD, Fellous TG, Johnson JR. Pericytes, mesenchymal stem cells and their contributions to tissue repair. *Pharmacol Ther*. (2015) 151:107–20. doi: 10.1016/j.pharmthera.2015.03.006
- Othman N, Jamal R, Abu N. Cancer-derived exosomes as effectors of key inflammation-related players. *Front Immunol*. (2019) 10:2103. doi: 10.3389/fimmu.2019.02103
- Kroemer G, Pouyssegur J. Review tumor cell metabolism : cancer 's achilles ' heel. *Cell Press*. (2008) 13:472–82. doi: 10.1016/j.ccr.2008.05.005
- Rodr AL, Arcia ED. Phenotypical characterization of regulatory T cells in humans and rodents. (2016). 281–91. doi: 10.1111/cei.12804
- Hadjimichael C, Chanoumidou K, Papadopoulou N, Arampatzi P, Papamatheakis J, Kretsovali A, et al. Common stemness regulators of embryonic and cancer stem cells. *World J Stem Cells*. (2015) 7:1150–84. doi: 10.4252/wjsc.v7.i9.1150
- Zhou Y, Xia L, Wang H, Oyang L, Su M, Liu Q, et al. Cancer stem cells in progression of colorectal cancer. *Oncotarget*. (2018) 9:33403–15. doi: 10.18632/oncotarget.23607
- Tsubakihara Y, Moustakas A. Epithelial-mesenchymal transition and metastasis under the control of transforming growth factor  $\beta$ . *Int J Mol Sci*. (2018) 19:1–30. doi: 10.3390/ijms19113672

24. Lv L, Liu H, Dong S, Yang F, Wang Q. Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells. *Tumor Biol.* (2016) 37:8811–24. doi: 10.1007/s13277-015-4755-6
25. Kim DH, Xing T, Yang Z, Dudek R, Lu Q, Chen Y. Epithelial mesenchymal transition in embryonic development, tissue repair and cancer : a comprehensive overview. *J Clin Med.* (2017) 7:1. doi: 10.3390/jcm7010001
26. Bendas G, Borsig L. Cancer cell adhesion and metastasis : selectins, integrins, and the inhibitory potential of heparins. *Int J Cell Biol.* (2012) 2012:676731. doi: 10.1155/2012/676731
27. Škovieřová H, Okajčėková T, Strnáděl JÁN. Molecular regulation of epithelial - to - mesenchymal transition in tumorigenesis (Review). *Int J Mol Med.* (2018) 41:1187–200. doi: 10.3892/ijmm.2017.3320
28. Ocaña O, Córcoles R, Fabra Á, Moreno-Bueno G, Acloque H, Vega S, et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prx1. *Cancer Cell.* (2012) 22:709–24. doi: 10.1016/j.ccr.2012.10.012
29. Lambert SA, Jolma A, Campitelli LF, Das PK, Yin Y, Albu M, et al. The human transcription factors. *Cell.* (2018) 172:650–65. doi: 10.1016/j.cell.2018.01.029
30. Xu W, Yang Z, Lu N. A new role for the PI3K / Akt signaling pathway in the epithelial-mesenchymal transition. *Cell Adh Migr.* (2015) 9:317–24. doi: 10.1080/19336918.2015.1016686
31. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. *Nat Rev Mol Cell Biol.* (2014) 15:178–96. doi: 10.1038/nrm3758
32. Hwang W-L, Yang M-H, Tsai M-L, Lan H-Y, Su S-H, Chang S-C, et al. SNAIL regulates interleukin-8 expression, stem cell–like activity, and tumorigenicity of human colorectal carcinoma cells. *Gastroenterology.* (2011) 141:279–91. doi: 10.1053/j.gastro.2011.04.008
33. Hu X. Proteolytic signaling by TNF  $\alpha$  : caspase activation and IJB degradation. *Cytokine.* (2003) 21:286–94. doi: 10.1016/S1043-4666(03)00107-8
34. Huang X, Xiang L, Li Y, Zhao Y, Zhu H, Xiao Y, et al. Snail/FOXK1 / Cyr61 signaling axis regulates the epithelial – mesenchymal transition and metastasis in colorectal cancer. *Cell hystology Biochem.* (2018) 47:590–603. doi: 10.1159/000490015
35. Abdelmaksoud-dammak R, Chamtourri N, Triki M, Saadallah-kallel A, Ayadi W, Charfi S, et al. Overexpression of miR-10b in colorectal cancer patients : correlation with TWIST-1 and E-cadherin expression. *Tumor Biol.* (2017) 39:1010428317695916. doi: 10.1177/1010428317695916
36. Segura ME, Jubierre L, Li S, Soriano A, Koetz L, Masanas M, et al. Krüppel-like factor 4 (KLF4) regulates the mir-183 96 182 cluster under physiologic and pathologic conditions. *Oncotarget.* (2017) 8:26298–311. doi: 10.18632/oncotarget.15459
37. Xu W, Hu Q, Qin Y, Zhang B, Liu W, Ni Q, et al. Zinc finger E-box-binding homeobox 1 mediates aerobic glycolysis via suppression of sirtuin 3 in pancreatic cancer. *World J Stem Cells.* (2018) 24:4893–905. doi: 10.3748/wjg.v24.i43.4893
38. Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M. The transcription factor ZEB1 ( $\delta$  EF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. *Oncogene.* (2007) 26:6979–88. doi: 10.1038/sj.onc.1210508
39. Ahn Y, Gibbons DL, Chakravarti D, Creighton CJ, Rizvi ZH, Adams HP, et al. ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. *J Clin Invest.* (2012) 122:3170–83. doi: 10.1172/JCI 63608
40. Chi Y, Zhou D. MicroRNAs in colorectal carcinoma - from pathogenesis to therapy. *J Exp Clin Cancer Res.* (2016) 35:43. doi: 10.1186/s13046-016-0320-4
41. Zaravinos A, Emt T. The regulatory role of MicroRNAs in EMT and cancer. *J Oncol.* (2015) 2015:13. doi: 10.1155/2015/865816
42. Sun W, Wang X, Li J, You C, Lu P, Feng H, et al. MicroRNA-181a promotes angiogenesis in colorectal cancer by targeting SRCIN1 to promote the SRC / VEGF signaling pathway. *Cell Death Dis.* (2018) 9:438. doi: 10.1038/s41419-018-0490-4
43. Liu Y, Liu R, Yang F, Cheng R, Chen X, Cui S, et al. miR-19a promotes colorectal cancer proliferation and migration by targeting. *Mol Cancer.* (2017) 16:53. doi: 10.1186/s12943-017-0625-8
44. Fu F, Jiang W, Zhou L. Circulating exosomal miR-17-5p and miR-92a-3p predict pathologic stage and grade of colorectal cancer. *Transl Oncol.* (2018) 11:221–32. doi: 10.1016/j.tranon.2017.12.012
45. Zhang Y, Weinberg RA. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. *Front Med.* (2018) 12:361–73. doi: 10.1007/s11684-018-0656-6
46. Baccelli I, Trumpp A. The evolving concept of cancer and metastasis stem cells. *J Cell Biol.* (2012) 198:281–93. doi: 10.1083/jcb.201202014
47. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. *Nat Rev Clin Oncol.* (2018) 14:611–29. doi: 10.1038/nrclinonc.2017.44
48. Yang C, Chen F, Wang S, Xiong B, Xiong B. Circulating tumor cells in gastrointestinal cancers : current status and future perspectives. *Front Oncol.* (2019) 9:1427. doi: 10.3389/fonc.2019.01427
49. Tellez-Gabriel M, Heymann M, Heymann D. Circulating tumor cells as a tool for assessing tumor heterogeneity. *Theranostics.* (2019) 9:4580–94. doi: 10.7150/thno.34337
50. Chu P, Clanton DJ, Snipas TS, Lee J, Mitchell E, Nguyen M, et al. Characterization of a subpopulation of colon cancer cells with stem cell-like properties. *Int J Cancer.* (2009) 124:1312–21. doi: 10.1002/ijc.24061
51. Kidess-Sigal E, Liu HE, Triboulet MM, Che J, Ramani C, Visser BC, et al. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform : Comparison to ctDNA and tissue in metastatic colorectal cancer. *Oncotarget.* (2016) 7:85349–64. doi: 10.18632/oncotarget.13350
52. Jagust P, De Luxán-Delgado B, Parejo-Alonso B, Sancho P. Metabolism-based therapeutic strategies targeting cancer stem cells. *Front Pharmacol.* (2019) 10:203. doi: 10.3389/fphar.2019.00203
53. Zhao Y, Dong Q, Li J, Zhang K, Qin J, Zhao J, et al. Targeting cancer stem cells and their niche: perspectives for future therapeutic targets and strategies. *Semin Cancer Biol.* (2018) 53:139–55. doi: 10.1016/j.semcancer.2018.08.002
54. Chae YC, Kim JH. Cancer stem cell metabolism: target for cancer therapy. *BMB Rep.* (2018) 51:319–26. doi: 10.5483/BMBRep.2018.51.7.112
55. Riestler M, Xu Q, Moreira A, Zheng J, Michor F, Downey RJ. The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation. *Ann Oncol.* (2018) 29:264–70. doi: 10.1093/annonc/mdx645
56. Intlekofer AM, Finley LWS. Metabolic signatures of cancer cells and stem cells. *Nat Metab.* (2019) 2:177–88. doi: 10.1038/s42255-019-0032-0
57. Brown RE, Short SP, Williams CS. Colorectal cancer and metabolism. *Curr Color Cancer Rep.* (2018) 14:226–41. doi: 10.1007/s11888-018-0420-y
58. Ghanbari Movahed Z, Rastegari-Pouyani M, Mohammadi M hossein, Mansouri K. Cancer cells change their glucose metabolism to overcome increased ROS: one step from cancer cell to cancer stem cell? *Biomed Pharmacother.* (2019) 112:108690. doi: 10.1016/j.biopha.2019.108690
59. Nallanthighal S, Heiserman JP, Cheon D-J. The role of the extracellular matrix in cancer stemness. *Front Cell Dev Biol.* (2019) 7:86. doi: 10.3389/fcell.2019.00086
60. Fang Y, Shen Z-Y, Zhan Y-Z, Feng X-C, Chen K-L, Li Y-S, et al. CD36 inhibits  $\beta$ -catenin/c-myc-mediated glycolysis through ubiquitination of GPC4 to repress colorectal tumorigenesis. *Nat Commun.* (2019) 10:3981. doi: 10.1038/s41467-019-11662-3
61. Someya T, Sano K, Hara K, Sagane Y, Watanabe T, Wijesekara RGS. Fibroblast and keratinocyte gene expression following exposure to extracts of neem plant (*Azadirachta indica*). *Data Br.* (2018) 16:982–92. doi: 10.1016/j.dib.2017.12.035
62. Fang C, Fan C, Wang C, Huang Q, Meng W, Yu Y, et al. Prognostic value of CD133+CD54+CD44+ circulating tumor cells in colorectal cancer with liver metastasis. *Cancer Med.* (2017) 6:2850–7. doi: 10.1002/cam4.1241
63. Sun YAN, Zhao X, Zhou Y, Hu YU. miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect. *Oncol Rep.* (2012) 28:1346–52. doi: 10.3892/or.2012.1958
64. Chen Z, Zuo X, Zhang Y, Han G, Zhang L, Wu J, et al. MiR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1  $\alpha$  -mediated Warburg effect. *Cell Death Dis.* (2018) 9:549. doi: 10.1038/s41419-018-0616-8
65. Miyoshi J, Toden S, Yoshida K, Toyama Y, Alberts SR, Kusunoki M, et al. MiR-139-5p as a novel serum biomarker for recurrence and metastasis

- in colorectal cancer. *Nat Publ Gr.* (2017) 7:43393. doi: 10.1038/srep43393
66. Li L, Liang Y, Kang L, Liu Y, Gao S, Chen S, et al. Transcriptional regulation of the warburg effect in cancer by six1 article transcriptional regulation of the warburg effect in cancer by SIX1. *Cancer Cell.* (2018) 33:368–85.e7. doi: 10.1016/j.ccell.2018.01.010
  67. Li L, Kang L, Zhao W, Feng Y, Liu W, Wang T, et al. miR-30a-5p suppresses breast tumor growth and metastasis through inhibition of LDHA-mediated Warburg effect. *Cancer Lett.* (2017) 400:89–98. doi: 10.1016/j.canlet.2017.04.034
  68. Liu X, Wang H, Liang X, Roberts MS. Hepatic metabolism in liver health and disease. *Liver Pathophysiol.* (2017) 391–400. doi: 10.1016/B978-0-12-804274-8.00030-8
  69. Ramos-Tovar E, Muriel P. Does nutrition matter in liver disease? *Liver Pathophysiol.* (2017) 743–59. doi: 10.1016/B978-0-12-804274-8.00053-9
  70. Hernández-Aquino E, Muriel P. Beneficial effects of naringenin in liver diseases: molecular mechanisms. *World J Gastroenterol.* (2018) 24:1679–707. doi: 10.3748/wjg.v24.i16.1679
  71. Hao Y, Samuels Y, Li Q, Krokowski D, Guan BJ, Wang C, et al. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. *Nat Commun.* (2016) 7:11971. doi: 10.1038/ncomms11971
  72. Li Q, Li Y, Xu J, Wang S, Xu Y, Li X, et al. Aldolase B overexpression is associated with poor prognosis and promotes tumor progression by epithelial-mesenchymal transition in colorectal adenocarcinoma. *Cell Physiol Biochem.* (2017) 42:397–406. doi: 10.1159/000477484
  73. Bu P, Chen K-Y, Xiang K, Johnson C, Crown SB, Rakhilin N, et al. Aldolase B mediated fructose metabolism drives metabolic reprogramming of colon cancer liver metastasis. *Cell Metab.* (2018) 6:1249–62. doi: 10.1016/j.cmet.2018.04.003
  74. Lee SY, Ju MK, Jeon HM, Lee YJ, Kim CH, Park HG, et al. Oncogenic metabolism acts as a prerequisite step for induction of cancer metastasis and cancer stem cell phenotype. *Oxid Med Cell Longev.* (2018) 2018:1027453. doi: 10.1155/2018/1027453
  75. Vecchia S La, Sebastián C. Metabolic pathways regulating colorectal cancer initiation and progression. *Semin Cell Dev Biol.* (2020) 98:63–70. doi: 10.1016/j.semdb.2019.05.018
  76. Kim JH, Lee KJ, Seo Y, Kwon JH, Yoon JP, Kang JY, et al. Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism. *Sci Rep.* (2018) 8:409. doi: 10.1038/s41598-017-18762-4
  77. Snyder V, Reed-Newman TC, Arnold L, Thomas SM, Anant S. Cancer stem cell metabolism and potential therapeutic targets. *Front Oncol.* (2018) 8:203. doi: 10.3389/fonc.2018.00203
  78. Sancho P, Barneda D, Heeschen C. Hallmarks of cancer stem cell metabolism. *Br J Cancer.* (2016) 114:1305–12. doi: 10.1038/bjc.2016.152
  79. Cheong J, Shin M. Mitochondria-centric bioenergetic characteristics in cancer stem-like cells. *Arch Pharm Res.* (2019) 42:113–27. doi: 10.1007/s12272-019-01127-y
  80. De Francesco EM, Sotgia F, Lisanti MP. Cancer stem cells (CSCs): metabolic strategies for their identification and eradication. *Biochem J.* (2018) 475:1611–34. doi: 10.1042/BCJ20170164
  81. Linden C Vander, Corbet C. Therapeutic targeting of cancer stem cells : integrating and exploiting the acidic niche. *Front Oncol.* (2019) 9:159. doi: 10.3389/fonc.2019.00159
  82. White KA, Grillo-hill BK, Barber DL. Cancer cell behaviors mediated by dysregulated pH dynamics at a glance. *J Cell Sci.* (2017) 130:663–9. doi: 10.1242/jcs.195297
  83. Krause P, Flikweert H, Monin M, Hosseini ASA, Helms G, Cantanhede G, et al. Increased growth of colorectal liver metastasis following partial hepatectomy. *Clin Exp Metastasis.* (2013) 30:681–93. doi: 10.1007/s10585-013-9572-y
  84. Tameemi W Al, Dale TP, Al-jumaily RMK, Forsyth NR. Hypoxia-modified cancer cell metabolism. *Front Cell Dev Biol.* (2019) 7:4. doi: 10.3389/fcell.2019.00004
  85. Ko M, Quiñones-hinojosa A, Rao R. Emerging links between endosomal pH and cancer. *Cancer Metastasis Rev.* (2020) 39:519–34. doi: 10.1007/s10555-020-09870-1
  86. Gupta VK, Jaiswara P, Kumar A. The emerging role of miR-NAs in tumor acidosis. *J Cell Biol Cell Metab.* (2018) 5:15. doi: 10.24966/CBCM-1943/100015
  87. Cho H, Han T, Hur K, Seung Ban H. The roles of hypoxia-inducible factors and non-coding RNAs in gastrointestinal cancer. *Genes.* (2019) 10:1008. doi: 10.3390/genes10121008
  88. Asgharzadeh MR, Barar J, Pourseif MM, Eskandani M, Niya MJ. Molecular machineries of pH dysregulation in tumor microenvironment : potential targets for cancer therapy. *Bioimpacts.* (2017) 7:115–33. doi: 10.15171/bi.2017.15
  89. Soon P, Kiaris H. MicroRNAs in the tumour microenvironment : big role for small players. *Endocr Relat Cancer.* (2013) 20:257–67. doi: 10.1530/ERC-13-0119
  90. Qi Y, Xu R. Roles of PLODs in collagen synthesis and cancer progression. *Front Cell Dev Biol.* (2018) 6:66. doi: 10.3389/fcell.2018.00066
  91. Wang D. High expression of PLOD1 drives tumorigenesis and affects clinical outcome in gastrointestinal carcinoma 1, 2 1. *Genet Test Mol Biomarkers.* (2018) 22:366–73. doi: 10.1089/gtmb.2018.0009
  92. Prager BC, Xie Q, Bao S, Rich JN, Diego S, Jolla L, et al. Cancer stem cells : the architects of the tumor ecosystem. *Cell Stem Cell.* (2019) 24:41–53. doi: 10.1016/j.stem.2018.12.009
  93. Markiewicz A, Zaczek AJ. The landscape of circulating tumor cell research in the context of epithelial-mesenchymal transition. *Pathobiology.* (2017) 84:264–83. doi: 10.1159/000477812
  94. Pardali E, Sanchez-Duffhues G, Gomez-Puerto MC, Dijke P. TGF- $\beta$ -induced endothelial-mesenchymal transition in fibrotic diseases. *Int J Mol Sci.* (2017) 18:2157. doi: 10.3390/ijms18102157
  95. Yeo CD, Kang N, Choi SY, Kim BN, Park CK, Kim JW, et al. The role of hypoxia on the acquisition of epithelial- mesenchymal transition and cancer stemness : a possible link to epigenetic regulation. *Korean J Intern Med.* (2017) 32:589–99. doi: 10.3904/kjim.2016.302
  96. Tan ST. Characterization of cancer stem cells in colon adenocarcinoma metastasis to the liver. *Front Surg.* (2018) 4:76. doi: 10.3389/fsurg.2017.00076
  97. Mcindoe G, Zealand N. Renin-angiotensin system and cancer : a review. *Integr Cancer Sci Ther.* (2017) 4:1–6. doi: 10.15761/ICST.1000231
  98. Wang L, Li C, Wang L, Yu W, Yin H, Zhang G, et al. Influence of CXCR4 / SDF-1 axis on E-cadherin /  $\beta$ -catenin complex expression in HT29 colon cancer cells. *World J Gastroenterol.* (2011) 17:625–32. doi: 10.3748/wjg.v17.i5.625
  99. Corliss BA, Azimi MS, Munson J, Peirce SM, Murfee L. Macrophages: an inflammatory link between angiogenesis and lymphangiogenesis. *Microcirculation.* (2017) 23:95–121. doi: 10.1111/micc.12259
  100. Palma M De, Biziato D, Petrova T V. Microenvironmental regulation of tumour angiogenesis. *Nat Rev.* (2017) 17:457–74. doi: 10.1038/nrc.2017.51
  101. Agnoletto C, Corr F, Minotti L, Baldassari F, Crudele F, Joseph W, et al. Heterogeneity in circulating tumor cells : the relevance of the stem-cell subset. *Cancers.* (2019) 11:9–12. doi: 10.3390/cancers11040483
  102. Malara N, Trunzo V, Foresta U, Amodio N, Vitis S De, Roveda L. *Ex-vivo* characterization of circulating colon cancer cells distinguished in stem and differentiated subset provides useful biomarker for personalized metastatic risk assessment *Ex-vivo* characterization of circulating colon cancer cells distinguished I. *J Transl Med.* (2016) 14:133. doi: 10.1186/s12967-016-0876-y
  103. Aguado BA, Bushnell GG, Rao SS, Jeruss JS, Shea LD. Engineering the pre-metastatic niche. *Nat Biomed Eng.* (2017) 1:0077. doi: 10.1038/s41551-017-0077
  104. Guo Y, Ji X, Liu J, Fan D, Zhou Q, Chen C, et al. Effects of exosomes on pre-metastatic niche formation in tumors. *Mol Cancer.* (2019) 18:39. doi: 10.1186/s12943-019-0995-1
  105. Zeng Z, Li Y, Pan Y, Lan X, Song F, Sun J, et al. Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. *Nat Commun.* (2018) 9:5395. doi: 10.1038/s41467-018-07810-w
  106. Conev N V, Donev IS, Konsoulova-kirova AA, Chervenkov TG. Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients. *Biosci Trends.* (2015) 9:393–401. doi: 10.5582/bst.2015.01170
  107. Cellura D, Pickard K, Quaratino S, Parker H, Strefford JC, Thomas GJ, et al. MiR-19-mediated inhibition of transglutaminase-2 leads to enhanced

- invasion and metastasis in colorectal cancer. *Mol Cancer Res.* (2016) 13:1095–105. doi: 10.1158/1541-7786.MCR-14-0466
108. Lam CS, Ng L, Chow AK, Wan TM, Yau S, Cheng NS, et al. Identification of microRNA 885-5p as a novel regulator of tumor metastasis by targeting CPEB2 in colorectal cancer. *Oncotarget.* (2017) 8:26858–70. doi: 10.18632/oncotarget.15844
  109. Cheng D, Zhao S, Tang H, Zhang D. MicroRNA-20a-5p promotes colorectal cancer invasion and metastasis by downregulating Smad4. *Oncotarget.* (2016) 7:45199–213. doi: 10.18632/oncotarget.9900
  110. Ding L, Lan Z, Xiong X, Ao H, Feng Y. The dual role of MicroRNAs in colorectal cancer progression. *Int J Mol Sci.* (2018) 19:2791. doi: 10.3390/ijms19092791
  111. Ji D, Chen Z, Li M, Zhan T, Yao Y, Zhang Z, et al. MicroRNA-181a promotes tumor growth and liver metastasis in colorectal cancer by targeting the tumor suppressor WIF-1. *Mol Cancer.* (2014) 13:86. doi: 10.1186/1476-4598-13-86
  112. Han Y, Zhao Q, Zhou J, Shi R. miR-429 mediates tumor growth and metastasis in colorectal cancer. *Am J Cancer Res.* (2017) 7:218–33.
  113. Huang S, Tan X, Huang Z, Chen Z, Lin P, Fu SW. microRNA biomarkers in colorectal cancer liver metastasis. *J Cancer.* (2018) 9:3867–73. doi: 10.7150/jca.28588
  114. Vasilaki E, Morikawa, M Koinuma D, Izutani A, Hirano Y, Ehata S, et al. Ras and TGF- $\beta$  signaling enhance cancer progression by promoting the  $\Delta$ Np63 transcriptional program. *Sci Signal.* (2016) 9:ra84. doi: 10.1126/scisignal.aag3232
  115. Badr EAE, Ali Assar MF, Gohar SF, Badr MH, Hathout RM, El-kousy SM. The clinical impact of miRNA34a and P53 gene expression in colon cancer. *Biochem Biophys Reports.* (2018) 16:88–95. doi: 10.1016/j.bbrep.2018.10.002
  116. Li W, Chang J, Tong D, Peng J, Huang D. Differential microRNA expression profiling in primary tumors and matched liver metastasis of patients with colorectal cancer. *Oncotarget.* (2017) 8:35783–91. doi: 10.18632/oncotarget.16206
  117. Wen XU, Wu J, Peng WEI, Feng J, Tang J. MicroRNA-377 predicts poor clinical outcome of gastric cancer and induces tumorigenesis by targeting multiple tumor-suppressor genes. *Oncol Rep.* (2015) 34:203–10. doi: 10.3892/or.2015.3981
  118. Torres S, Garcia-Palmero I, Bartolomé RA, Fernandez-Aceñero MJ, Molina E, Calviño E, et al. Combined miRNA profiling and proteomics demonstrates that different miRNAs target a common set of proteins to promote colorectal cancer metastasis. *J Pathol.* (2017) 242:39–51. doi: 10.1002/path.4874
  119. Vyčhítlová-Faltesková P, Pesta M, Radova L, Liska V, Daum O, Kala Z, et al. Genome-wide microRNA expression profiling in primary tumors and matched liver metastasis of patients with colorectal cancer. *Cancer Genomics Proteomics.* (2016) 13:311–6.
  120. Bleau AM, Redrado M, Nistal-Villan E, Villalba M, Exposito F, Redin E, et al. miR-146a targets c-met and abolishes colorectal cancer liver metastasis. *Cancer Lett.* (2018) 414:257–67. doi: 10.1016/j.canlet.2017.11.008
  121. Lu D, Yao Q, Zhan C, Le-meng Z, Liu H, Cai Y. MicroRNA-146a promote cell migration and invasion in human colorectal cancer via carboxypeptidase M / src-FAK pathway. *Oncotarget.* (2017) 8:22674–84. doi: 10.18632/oncotarget.15158
  122. Yan H, Zhang Y, Wang C, Qiu D, Zhou K, Hua Y, et al. miRNAs as biomarkers for diagnosis of heart failure. *Medicine.* (2017) 22:e6825. doi: 10.1097/MD.0000000000006825
  123. Pecqueux M, Liebetrau I, Werft W, Dienemann H, Muley T, Pfanschmidt J, et al. A comprehensive microRNA expression profile of liver and lung metastases of colorectal cancer with their corresponding host tissue and its prognostic impact on survival. *Int J Mol Sci.* (2016) 17:1755. doi: 10.3390/ijms17101755
  124. Yin J, Bai Z, Song J, Yang Y, Wang J, Han W, et al. Differential expression of serum miR-126, miR-141 and miR-21 as novel biomarkers for early detection of liver metastasis in colorectal cancer. *Chinese J Cancer Res.* (2014) 26:95–103. doi: 10.3978/j.issn.1000-9604.2014.02.07
  125. Matsumura T, Sugimachi K, Inuma H, Takahashi Y, Kurashige J, Sawada G, et al. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. *Br J Cancer.* (2015) 113:275–81. doi: 10.1038/bjc.2015.201
  126. Argyle D, Kitamura T. Targeting macrophage-recruiting chemokines as a novel therapeutic strategy to prevent the progression of solid tumors. *Front Immunol.* (2018) 9:2629. doi: 10.3389/fimmu.2018.02629
  127. Nguyen A V, Wu Y, Lin EY. STAT3 and sphingosine-1-phosphate in inflammation-associated colorectal cancer. *World J Gastroenterol.* (2014) 20:10279–87. doi: 10.3748/wjg.v20.i30.10279
  128. Liberti M V., Locasale JW. The warburg effect: how does it benefit cancer cells? *Trends Biochem Sci.* (2016) 41:211–8. doi: 10.1016/j.tibs.2015.12.001
  129. Zhang R, Qi F, Zhao F, Li G, Shao S, Zhang X, et al. Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer. *Cell Death Dis.* (2019) 10:273. doi: 10.1038/s41419-019-1435-2
  130. Valderrama-Treviño AI, Barrera-Mera B, Ceballos-Villalva JC, Montalvo-Javé EE. Hepatic metastasis from colorectal cancer. *Euroasian J Hepato-Gastroenterol.* (2017) 7:166–75. doi: 10.5005/jp-journals-10018-1241
  131. Brodt P. Role of the microenvironment in liver metastasis : from pre- to prometastatic niches. *Clin Cancer Res.* (2016) 22:5971–83. doi: 10.1158/1078-0432.CCR-16-0460
  132. Paschos KA, Majeed AW, Bird NC, Paschos KA, Majeed AW, Bird NC. Natural history of hepatic metastases from colorectal cancer - pathobiological pathways with clinical significance. *World J Gastroenterol.* (2014) 20:3719–37. doi: 10.3748/wjg.v20.i14.3719
  133. Ren B, Cui M, Yang G, Wang H, Feng M, You L, et al. Tumor microenvironment participates in metastasis of pancreatic cancer. *Mol Cancer.* (2018) 17:108. doi: 10.1186/s12943-018-0858-1
  134. Hu C, Guo L, Feng N, Zhang L, Zhou N, Ma L. MIF, secreted by human hepatic sinusoidal endothelial cells, promotes chemotaxis and outgrowth of colorectal cancer in liver prometastasis. *Oncotarget.* (2015) 6:22410–23. doi: 10.18632/oncotarget.4198
  135. Soster M, Cardaci S, Muratore A, Bartolini A, Barone V, Ribero D, et al. A complex of a 6 integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiotensin-like 6. *EMBO Mol Med.* (2012) 4:1156–75. doi: 10.1002/emmm.201101164
  136. Li JH, Delman D, Graham K, Gladney WL. Hepatocytes direct the formation of a pro-metastatic niche in the liver. *Nature.* (2019) 567:249–52. doi: 10.1038/s41586-019-1004-y
  137. Pedrosa L, Esposito F, Thomson T, Maurel J. The tumor microenvironment in colorectal cancer. *Cancers.* (2019) 11:1172. doi: 10.3390/cancers11081172
  138. Zhang L, Zhao Y, Dai Y, Cheng JN, Gong Z, Feng Y, et al. Immune landscape of colorectal cancer tumor microenvironment from different primary tumor location. *Front Immunol.* (2018) 9:1578. doi: 10.3389/fimmu.2018.01578
  139. Lee JH, Lee S. The roles of carcinoembryonic antigen in liver metastasis and therapeutic approaches. *Gastroenterol Res Pract.* (2017) 2017:11. doi: 10.1155/2017/7521987
  140. Abdul-wahid A, Cydzik M, Fischer NW, Prodeus A, John E, Alminawi S, et al. Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells. *Int J Cancer.* (2018) 143:1963–77. doi: 10.1002/ijc.31586
  141. Gu S, Zaidi S, Hassan I, Mohammad T, Noushmehr H, Nguyen B, et al. Mutated CEACAMs disrupt transforming growth factor betasignaling and alter the intestinal microbiome to promotecolorectal carcinogenesis. *Gastroenterology.* (2020) 158:238–52. doi: 10.1053/j.gastro.2019.09.023
  142. Eiro N, Gonzalez LO, Cid S, Schneider J, Vizoso FJ. Breast cancer tumor stroma : cellular components, therapeutic opportunities. *Cancers (Basel).* (2019) 11:664. doi: 10.3390/cancers11050664
  143. Rattila S, Dunk CE, Im M, Grichenko O, Zhou Y, Cohen M, et al. Interaction of pregnancy-specific glycoprotein 1 with trophoblast functions. *Cells.* (2019) 8:1369. doi: 10.3390/cells8111369
  144. Miyazaki K, Oyanagi J, Hoshino D, Togo S, Kumagai H, Miyagi Y. Cancer cell migration on elongate protrusions of fibroblasts in collagen matrix. *Sci Rep.* (2019) 9:292. doi: 10.1038/s41598-018-36646-z
  145. Yan C, Hu Y, Zhang B, Mu L, Huang K, Zhao H, et al. The CEA-/lo colorectal cancer cell population harbors cancer stem cells and metastatic cells. *Oncotarget.* (2016) 7:80700–15. doi: 10.18632/oncotarget.13029
  146. Wang X, Yang Z, Tian H, Li Y, Li M, Zhao W, et al. Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with

- liver metastasis and poor survival in colorectal cancer. *Oncotarget*. (2017) 8:24892–901. doi: 10.18632/oncotarget.15279
147. Rizeq B, Zakaria Z, Ouhittit A. Towards understanding the mechanisms of actions of carcinoembryonic antigen-related cell adhesion molecule 6 in cancer progression. *Cancer Sci*. (2018) 109:33–42. doi: 10.1111/cas.13437
  148. Yamashita S, Chun YS, Kopetz SE, Vauthey JN. Biomarkers in colorectal liver metastases. *Br J Surg*. (2018) 105:618–27. doi: 10.1002/bjs.10834
  149. Sakai E, Nakayama M, Oshima H, Kouyama Y, Niida A, Fujii S, et al. Combined mutation of Apc, Kras, and Tgfr2 effectively drives metastasis of intestinal cancer. *Cancer Res*. (2018) 78:1334–46. doi: 10.1158/0008-5472.CAN-17-3303
  150. Tsilimigras DI, Ntanasis-Stathopoulos I, Bagante F, Moris D, Cloyd J, Spartalis E, et al. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: a systematic review of the current evidence. *Surg Oncol*. (2018) 27:280–8. doi: 10.1016/j.suronc.2018.05.012
  151. Porru M, Pompili L, Caruso C, Biroccio A, Leonetti C. Targeting kras in metastatic colorectal cancer: current strategies and emerging opportunities. *J Exp Clin Cancer Res*. (2018) 37:57. doi: 10.1186/s13046-018-0719-1
  152. Nash GM, Gimbel M, Shia J, Nathanson DR, Nduubuisi MI, Zeng ZS, et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. *Ann Surg Oncol*. (2010) 17:572–8. doi: 10.1245/s10434-009-0605-3
  153. Giordano G, Remo A, Porras A, Pancione M. Immune resistance and egfr antagonists in colorectal cancer. *Cancers*. (2019) 11:1089. doi: 10.3390/cancers11081089
  154. Chang YS, Ke TW, Chang JG. Molecular characterization of colorectal cancer using whole - exome sequencing in a Taiwanese population. *Cancer Med*. (2019) 8:3738–47. doi: 10.1002/cam4.2282
  155. Pandurangan A kumar, Divya T, Kumar K, Dineshbabu V, Velavan B, Sudhandiran G. Colorectal carcinogenesis: insights into the cell death and signal transduction pathways: a review. *World J Gastroenterol Oncol*. (2018) 10:244–59. doi: 10.4251/wjgo.v10.i9.244
  156. Feng Q, Wang H, Pang J, Ji L, Han J, Wang Y, et al. Prevention of wogonin on colorectal cancer tumorigenesis by regulating p53 nuclear translocation. *Front Pharmacol*. (2018) 9:1356. doi: 10.3389/fphar.2018.01356
  157. Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. *Cell Death Differ*. (2019) 26:199–212. doi: 10.1038/s41418-018-0246-9
  158. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL. Gene set enrichment analysis : a knowledge-based approach for interpreting genome-wide. *Proc Natl Acad Sci USA*. (2005) 102:15545–50. doi: 10.1073/pnas.0506580102
  159. Soussi T. p53 antibodies in the sera of patients with various types of cancer: a review. *Cancer Res*. (2000) 60:1777–88.
  160. Nakayama M, Oshima M. Mutant p 53 in colon cancer. *J Mol Cell Biol*. (2019) 11:267–76. doi: 10.1093/jmcb/mjy075
  161. Romaine SPR, Tomaszewski M, Condorelli G, Samani NJ. MicroRNAs in cardiovascular disease : an introduction for clinicians. *Heart*. (2015) 101:921–8. doi: 10.1136/heartjnl-2013-305402
  162. Román-Rosales AA, García-Villa E, Herrera LA, Gariglio P, Díaz-Chávez J. Mutant p53 gain of function induces HER2 over-expression in cancer cells. *BMC Cancer*. (2018) 18:709. doi: 10.1186/s12885-018-4613-1
  163. Eswaran J, Horvath A, Godbole S, Reddy SD, Mudvari P, Ohshiro K, et al. RNA sequencing of cancer reveals novel splicing alterations. *Sci Rep*. (2013) 3:1689. doi: 10.1038/srep01689
  164. Nguyen HT, Duong H-Q. The molecular characteristics of colorectal cancer : implications for diagnosis and therapy (Review). *Oncol Lett*. (2018) 16:9–18. doi: 10.3892/ol.2018.8679
  165. Wang F, Cao C, Han K, Zhao Y, Cai M, Xiang Z, et al. APC-activated long noncoding RNA inhibits colorectal carcinoma pathogenesis through reduction of exosome production. *J Clin Invest*. (2019) 129:727–43. doi: 10.1172/JCI122478
  166. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. *J Hepatol*. (2018) 6:226–41. doi: 10.1016/j.jhep.2018.09.014
  167. Koury J, Zhong L, Hao J. Targeting signaling pathways in cancer stem cells for cancer treatment. *Stem Cells Int*. (2017) 2017:2925869. doi: 10.1155/2017/2925869
  168. Sun H, Wang S, Yan S, Zhang Y, Nelson PJ, Jia H. Therapeutic strategies targeting cancer stem cells and their microenvironment. *Front Oncol*. (2019) 9:1104. doi: 10.3389/fonc.2019.01104
  169. Sonbol MB, Ahn DH, Bekaii-saab T. Therapeutic targeting strategies of cancer stem cells in gastrointestinal malignancies. *Biomedicines*. (2019) 7:17. doi: 10.3390/biomedicines7010017
  170. Stein A. Immunotherapy of colon cancer. *Oncol Res Treat*. (2018) 41:282–5. doi: 10.1159/000488918
  171. Wang Y, Chen M, Wu Z, Tong C, Dai H, Guo Y, et al. CD133-directed CAR T cells for advanced metastasis malignancies : a phase I trial. *Oncoimmunology*. (2018) 7:e1440169. doi: 10.1080/2162402X.2018.1440169
  172. Akinleye A. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. *J Hematol Oncol*. (2019) 12:92. doi: 10.1186/s13045-019-0779-5
  173. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med*. (2015) 372:2509–20. doi: 10.1056/NEJMc1510353
  174. Wagner S, Mullins CS, Linnebacher M, Wagner S, Mullins CS, Linnebacher M, et al. Colorectal cancer vaccines : tumor-associated antigens vs neoantigens. *World J Gastroenterol*. (2018) 24:5418–32. doi: 10.3748/wjg.v24.i48.5418

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Gonzalez-Villarreal, Quiroz-Reyes, Islas and Garza-Treviño. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.